Short answer
Erasca, Inc. (ERAS) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$183M
- −492.4% YoY
- EPS (diluted)
- −$0.60
- −445.5% YoY
Source: XBRL data from the Erasca, Inc. (ERAS) Q1 2026 10-Q on SEC EDGAR. USD.
Erasca, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net loss $183.4M vs $31.0M YoY, operating margin not disclosed
- ERAS-0015 R&D $13.8M vs $6.5M, strongest program spending growth
- Cash, equivalents, and marketable securities $408.5M at March 31, 2026
- January offering net proceeds $242.7M, funding expected into second half of 2028
Risk Factors
- New RevMed patent dispute triggered by April 24, 2026 letter alleging ERAS-0015 infringes U.S. Patent No. 12,409,225
- Most material update: potential ERAS-0015 injunction or monetary damages following threatened RevMed litigation
- Trade-secret compliance exposure from allegations that ERAS-0015 was derived from RevMed proprietary information
- Near-term development risk from possible required product modifications, licensing, or commercialization-plan changes
- Disclosure risk from RevMed allegations concerning comparative preclinical statements about ERAS-0015 and RMC-6236
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Erasca, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.